HHLR Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

HHLR Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-114,042	Closed	-$10.1M	–	53
2023 Q3	$10.1M	Sell	114,042 -114,900	-50%	-$10.2M	0.23%	35
2023 Q2	$19.8M	Sell	228,942 -79,751	-26%	-$7.51M	0.42%	27
2023 Q1	$30M	Buy	+308,693	New	+$32M	0.53%	25

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

HHLR Advisors's BMRN Position: Q4 2023 in Review

HHLR Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 114,042 shares — an estimated $10.1M sold.

HHLR Advisors first reported a position in BMRN in Q1 2023 and held it in 3 quarters. The position peaked at $30M in Q1 2023. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

HHLR Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
HHLR Advisors sold 114,042 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $10.1M.
HHLR Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 3 quarters.
HHLR Advisors's BioMarin Pharmaceuticals position peaked at $30M in Q1 2023.
547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on HHLR Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.